T. J. Kipps Et Al. , "11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies," 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , vol.128, California, United States Of America, 2016
Kipps, T. J. Et Al. 2016. 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , (California, United States Of America).
Kipps, T. J., Hillmen, P., DEMİRKAN, F., Grosicki, S., Coutre, S. E., Barrientos, J. C., ... Barr, P. M.(2016). 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies . 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America
Kipps, Thomas Et Al. "11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies," 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 2016
Kipps, Thomas J. Et Al. "11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , California, United States Of America, 2016
Kipps, T. J. Et Al. (2016) . "11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , California, United States Of America.
@conferencepaper{conferencepaper, author={Thomas J. Kipps Et Al. }, title={11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies}, congress name={58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)}, city={California}, country={United States Of America}, year={2016}}